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Prevention and treatment of the postthrombotic
syndrome
Peter Henke, MD, on behalf of writing group I of the Pacific Vascular Symposium 6, Ann Arbor, MichTOPIC 1
Prevent recurrence of DVT
Background. Recurrent ipsilateral deep venous throm-
bosis (DVT) is a primary and probably the most important
etiologic factor in the development of the postthrombotic
syndrome (PTS).1,2 Reducing the rate of recurrent DVT
will thereby decrease the incidence of PTS. This can only be
accomplished bymodifying approaches to the current med-
ical management of primary DVT. Furthermore, capitaliz-
ing on available strategies, such as patient and physician
education, establishing hospital wide protocols for the pre-
vention and treatment of DVT, and adherence to consen-
sus guidelines, will help to optimize the treatment of DVT
and thereby reduce the rate of recurrent DVT.
The following issues are paramount to realizing a pri-
mary goal of recurrent DVT prevention (Table I): 1) iden-
tification of subgroups of patients who are at risk for
recurrence, as DVT is heterogeneous with regard to ana-
tomic extent, provoked by identified risk factors versus
unprovoked, and cancer- versus non-cancer-related;3,4 2)
optimizing the initiation, duration, and type of anticoagu-
lation for each patient, including maintaining appropriate
intensity of oral anticoagulation;5-7 3) provision of anti-
thrombotic prophylaxis to high risk medical and surgical
patients;4,8,9 and 4) educating patients and front-line phy-
sicians regarding appropriate DVT management and risks
of recurrent DVT.10,11 Preventing recurrent DVT will also
reduce the incidence of pulmonary embolism (PE) and
PE-associated mortality.12
Evidence. A number of studies have attempted to
identify factors that could be used to risk stratify DVT
patients with regard to risk of recurrence. Identification of
residual venous thrombosis on ultrasound has been associ-
ated with an increased incidence of recurrent DVT, sug-
gesting that an abnormal vein wall predisposes to recurrent
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ing thrombosis-thrombolysis state.13-15 However, stan-
dard criteria or definitions to guide ultrasonographic char-
acterization of residual venous thrombus are lacking.
Furthermore, ultrasound diagnosis of residual venous
thrombus is hampered by the wide variability in sonogra-
phy technique between users and institutions. For example,
there are no Intersocietal Commission for Accreditation of
Vascular Laboratories guidelines for characterizing this
finding. Some studies have reported that elevated D-dimer
levels could be useful for predicting the risk of recurrent
DVT, but this requires the patient being off anticoagula-
tion for 1 month prior to determining whether to cease or
continue therapy.16,17 It is unclear what the DVT risk is
during this interval, although it is probably low.18 More-
over, while D-dimer is very sensitive, it is not specific and
thus not as useful to ‘rule in’ a DVT. Thirdly, the use of
other biomarkers to further stratify the risk of recurrence is
an understudied area. Initial work has demonstrated a role
for inflammatory markers such as P-selectin, ICAM-1, and
IL-6 in DVT as well as PTS.19,20 Finally, it is equally
important to determine who is at low risk for DVT recur-
rence as it is to determine those likely to recur.21 Two large
studies suggest long-term vitamin K antagonist VKA use is
safe for preventing recurrent DVT, but the duration and
intensity varies.22,23 Such stratification could assist in man-
agement decisions as to the appropriate duration of antico-
agulation so as to reduce the risk of bleeding inherent to all
anticoagulants.24 Finally, population data as to the rate of
recurrent DVT, compared with rates of primary DVT, as
well as identification of additional risk factors for unpro-
voked DVT, are needed.
Means to achieve goals. Practical measures to achieve
a reduction in recurrent DVT include: promoting and
disseminating best practice guidelines (eg, as are currently
available in the American College of Chest Physicians
[ACCP] guidelines);25 to establish a new International
Classification of Diseases, Revision 9 (ICD-9) code for
recurrent DVT that can be used for nationwide administra-
tive tracking; producing a patient education handout and
widespread teaching web seminars on reducing the risk of
recurrent DVT; and harnessing the electronic medical
record to flag patients at high recurrence risk. The elec-
tronic medical record could be modified to automatically
flag high risk patients (by key words in the medical record
such as ‘iliofemoral DVT,’ occluded common femoral vein,
etc.). Realistically, this will have to occur at a local level.
There is already high quality evidence that electronic re-
minders directed to physicians increase the use of throm-
21S
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similar approaches could be tried to reduce the risk of
recurrent DVT. Providing a ‘DVT information card’ to
patients, to be given to their physician when admitted to
the hospital, would assure that the health care team is aware
of a patient’s prior history of DVT. The new oral antico-
agulants may lead to better compliance and safer, more
uniform intensity of anticoagulation.27
Recommendations and actions. The measures to
track success include following change in ICD-9, (ICD-10
Clinical Modification [CM]) codes, to propose a registry
with anticoagulation and ultrasound use in patients with
recurrent DVT, and to create a survey to assess adherence
to current DVT treatment guidelines. Success will also be
measured by whether we can achieve partnerships with
industry to create and distribute DVT identification cards.
These could be packaged with compression stockings and
low-molecular weight heparin that are prescribed for the
initial DVT. The best practice guideline would be inter-
faced with the Venous Disease Coalition meeting (VDC),
September, 2010 with action plans for distribution.
Timeline. Educational materials could be created
within 1 to 2 years. The registry, petition for ICD-10 code
addition, and patient cards may take significantly longer to
complete, depending on availability of funding.
TOPIC 2
Effective compression/ambulation
Background. The effects of elastic compression stock-
ings (ECS) following DVT have been well described, with
such benefits as reduction in venous hypertension, de-
creased edema, and improvements in the tissue microcircu-
lation.28 Furthermore, the effectiveness of ECS in the
prevention of PTS has been demonstrated in prospective
randomized trials.29,30 Additionally, when ECS are com-
bined with early ambulation, rates of PTS are de-
creased.31,32 However, despite the well-documented ben-
efit of early compression, the use of ECS is not universal,
even amongst vascular specialists.33,34 Moreover, patient
compliance is decreased by the difficulty of putting stock-
ings on, discomfort, and cost.33
The following issues are identified to improve the use of
Table I. Prevention of DVT recurrence
Factors Evidence level
Maintain adequate level of AC I C AC
Proper prophylaxis for high risk patients I A AC
r
Type of AC II B Ed
Maintain adequate duration of AC I C Du
m
Compression I A Ra
AC, Anticoagulation;ACCP, American College of Chest Physicians; LMWH
VKA, vitamin K antagonist.and compliance with compression and ambulation. First,there needs to be a consensus for standardization of the
type of medical compression used, its time of initiation, and
duration of use for acute DVT as well as PTS prevention
and treatment. This includes incorporating the concept of
immediate compression into the acute DVT treatment
setting. For example, patients who are discharged from the
emergency room should be prescribed either ECS or tem-
porary elastic wraps as part of the treatment of acute DVT.
This practice is consistent with current ACCP guidelines.35
Second, establishing closer partnerships with the medical
compression industry is necessary to encourage the devel-
opment of more comfortable and user-friendly products,
with the expectation that this will improve patient accep-
tance and compliance. In addition, direct communication
between industry representatives and patients needs to be
established so as to provide product support for patients
who are experiencing difficulties using ECS. Product sup-
port could be offered in the clinic setting, by telephone,
electronic mail, or on company websites.
Evidence. Important questions remain as to the true
magnitude of effectiveness and general feasibility of using
ECS to prevent PTS in patients with DVT.36 First, previous
trials had various limitations that could affect their validity
and generalizability, including modest sample size, recruit-
ment at a single center, lack of placebo control, and lack of
blinding of assessors. Although ECS are unlikely to cause
harm, they are difficult to apply, uncomfortable, expensive,
and require replacement every few months. It is unknown
what the duration of ECS is that offers the prescribed
amount of compression before wearing out. The SOX
Trial, an ongoing large multi-center blinded trial that is
comparing active versus placebo stockings to prevent PTS
after proximal DVT, is anticipated to provide important
additional information on the effectiveness of ECS.37
Second, it is not definitively known whether ECS are
effective in patients with symptomatic distal DVT, because
the above-mentioned trials enrolled only patients with
proximal DVT. Third, it is unclear whether ECS prevent
PTS or merely palliate it, in which case it may be equally
effective andmore convenient for patients to initiate the use
of ECS at the time of onset of PTS. Fourth, evaluation of
the effectiveness of ECS with lighter (20-30 mm Hg)
ools to facilitate Gaps in knowledge
cal services Type of AC and effect on recurrence
uidelines risk strata and
ders
Group versus individual prophylaxis;
prolonged prophylaxis
n New agent effects on PTS LMWH
vs VKA for PTS prevention.
US, d-dimer
rement, Education
Biomarkers to better determine risk
of recurrence.
acement Compliance; Duration of
compression and PTS incidence.
weight molecular heparin; PTS, postthrombotic syndrome;US, ultrasound;T
clini
CP g
emin
ucatio
plex
easu
pid plcompression strength to prevent PTS is necessary, as these
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for older patients. Of note, these two levels of compression
appear to have similar effectiveness in preventing recurrent
venous ulcer.38
Finally, it is unknown for how long ECS need to be
worn. Although the trials to date evaluated the use of ECS
for 2 years or longer, a recent trial reported that beyond an
initial 6-month period of use, there was no incremental
benefit in prolonging compression therapy for an addi-
tional 18 months.39 These observations suggest that the
use of ECS for 6 months might be adequate, and would be
easier for patients to tolerate than the currently recom-
mended 2 years of use.
Means to achieve goals. Practical measures to achieve
these objectives include increased contact with representa-
tives of ECS companies, who would be encouraged to
come to the physician’s office and emergency rooms to
disseminate compression and ambulation guidelines, and
to increase research and development with the aim of
improving compliance with compression. Patient educa-
tion based in the emergency room or ambulatory setting is
critical, as many patients with acute DVT are treated as
outpatients.
Recommendations and actions. One measure of
tracking success would be to determine stocking sales and
distribution now, and again in 5 years time. While this is a
surrogate for actual use, as a first step it would reflect ECS
prescribing practices by physicians. Second, a focused
emergency room (ER) physician survey on knowledge and
practices with regard to ECS should be performed before
and after focused education on the value of early ECS.
Third, to specifically target the ER discharge information
section of the chart, as well as the ER physicians, to ensure
that patients are discharged with appropriate compression
wrapping and stockings, in addition to their anticoagulants.
Forth, another potential avenue to improving the use of
compression after DVT may be to utilize the Veteran’s
Affairs medical centers and their electronic medical record
and information technology systems to implement early
pilot education and protocol programs for veterans in a
consistent and captive patient population. Two areas that
require further study include first, the use of dynamic pulse
compression as adjunctive therapy for PTS; and second,
developing the capability of embedding strength and stock-
ing use microchip data within stockings.
Timeline. We anticipate that education and survey
material could be distributed within 2 years, and a provider
survey (listed above) analysis could be achieved in 5 years.
We also anticipate partnering with the VDC to assist with
the educational effort.
TOPIC 3
Early thrombus removal in the patient with
iliofemoral involvement
Background. The effective use of anticoagulation in
DVT is known to reduce the risk of thrombus propagation,
pulmonary embolism, and recurrent DVT. However, anti-coagulation alone imperfectly protects against the occur-
rence of venous obstruction and valvular destruction, re-
sulting in ambulatory venous hypertension and potentially
PTS.40 Some data suggests that prolonged low-molecular-
weight heparin (LMWH) may be more effective than a
VKA to promote vein recanalization and thereby reduce
PTS.41,42 Modest data suggest those with extensive DVT
involving the iliofemoral segments are at excessive risk for
postthrombotic morbidity.43,44 Early surgical thrombec-
tomy and thrombus removal for iliofemoral DVT has been
shown to decrease vein wall injury, preserve valve function,
and ultimately decrease the occurrence of the PTS.45,46
Catheter-directed thrombolysis (CDT) has also been dem-
onstrated in prospective randomized trials as an acceptable
method of clot removal, with short term patency rates
rivaling open thrombectomy.47,48 Furthermore, CDT for
the treatment of DVT results in improved quality of life
when compared with anticoagulation alone, as well as
decreased postthrombotic morbidity.49,50 Thus, maximiz-
ing thrombus removal with catheter-based techniques is
likely to be an important component to reducing PTS. In
fact, it has been adopted by the 2008 ACCP guidelines,
although is not a strong recommendation.6
Evidence. Despite the ACCP guidelines and two pro-
spective randomized trials, much controversy surrounds
the optimal use of early clot removal for the prevention of
PTS, in part due to a lack of large, multicenter trials
addressing the effectiveness and safety of this approach
(Table II). The optimal timing of intervention and even the
definition of “early thrombus removal” is unknown. Acute
thrombus has been shown to respond better to thrombol-
ysis than chronic organized DVT.51 Anecdotally and arbi-
trarily, CDT is used within a window of approximately 14
days. The use of catheter-based mechanical thrombectomy
for thrombus resolution has also been well described.52
Combined pharmacomechanical lysis has the benefit of
decreased treatment time, amount of thrombolytic used,
cost, and hospital and intensive care unit stay.53 However,
whether this benefit will translate into decreased rates of
PTS is unknown. Currently, the most effective pharmaco-
mechanical thrombolytic regimen is unknown, as there
have been no head to head comparisons of the multiple
devices and lytic agents.54,55 Furthermore, the role of
venous stenting after lysis has not been established. It is
unknown if routine stenting following lysis improves pa-
tency or whether stent use should be limited to selected
Table II. Early DVT removal techniques
Methods Evidence Gaps in data
Open thrombectomy I B Who is best treated?
Pharmacological II A Timing?
Catheter mechanical II A Sequential levels of thrombus
clearance for best
outcome?
Angioplasty/stenting II Bcases with underlying anatomic or structural lesions. In
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who will benefit from surgical creation of an arteriovenous
fistula. The clinical benefit and long-term outcome of ag-
gressive thrombus removal in the femoral-popliteal seg-
ment is yet to be determined. Finally, the optimal surveil-
lance of recurrence of thrombosis protocol after thrombus
removal, choice of long-term anticoagulant, and the vein
wall response after the procedure is completed requires
study. An important area of future research is to assess new
technology for removal of subacute clot (14 days), and to
more exactly define thrombus age using biomarkers.
Means to achieve goals. Practical measures to achieve
these objectives are to ensure early referral of patients with
iliofemoral and extensive thrombosis to venous specialists;
and to establish a “red flag” notification system from the
vascular laboratory when common femoral vein occlusion is
detected, and alert the appropriate physicians. Further, to
better promulgate an accepted anatomical classification
system56 for the location and extent of the thrombus, (such
as iliofemoral vein involvement, instead of proximal vs
distal vein). Education of entry point providers, duplex
quantification of flow, and studies to track femoral popliteal
thrombus removal are also considered to be important. We
wish to develop a summary of relevant literature and infor-
mation on the appropriate use of thrombolysis to circulate
to the ER and primary care physicians to educate them on
timely referral of these patients. Finally, providing informa-
tion to providers at major vascular and nonvascular societies
about the thrombolysis registry, as well as the Acute
Venous Thrombosis: Thrombus Removal with Adjunctive
Catheter-Directed Thrombolysis (ATTRACT) trial, is
necessary.
Recommendations and actions. Measures of success
will be to follow and (as applicable) participate in the
ATTRACT trial, a National Institutes of Health-sponsored
multicenter trial to test the hypothesis that active thrombus
removal plus best medical therapy is superior to best med-
ical therapy in preventing PTS at 2 years. Another measure
will be to abstract ICD-9 CM codes related to deep venous
catheter inventions from Medicare population and to de-
termine the number of procedures being performed now
and in 5 years time. Thirdly, creation of an American
Venous Forum thrombolysis registry is underway. Market-
ing this registry to various groups and obtaining their input
and patient data would be valuable.
Timeline. Our timeline for achieving these landmarks
to partner with the VDC would be approximately 2 years.
TOPIC 4
Elimination of chronic postthrombotic obstruction of
iliofemoral venous segments
Background. Chronic obstruction of the iliofemoral
segment following acute DVT is common, as only 20% to
30% of the iliac vein thrombi recanalize with anticoagula-
tion alone.57 Proximal venous obstruction, independent of
reflux, is the principal cause of PTS in approximately one-
third of cases.57,58 Historically, proximal iliofemoral ob-struction has been treated surgically with iliocaval and
femorocaval bypass, endophlebectomy, or femoro-femoral
bypass (Palma procedure). However, percutaneous en-
dovenous venoplasty and stenting has replaced surgery as
the method of choice for venous outflow obstruction, with
primary and assisted-primary patency rates of 57% and 80%,
respectively, at 72 months for thrombotic disease.58
Identification of patients with proximal venous outflow
obstruction should not be limited to those with a history of
DVT, as symptoms of chronic venous insufficiency (CVI)
have been shown to develop as frequently in patients with
nonthrombotic iliac vein lesions, such as intraluminal webs
or extrinsic iliac vein compression.58,59 Chronic obstruc-
tion secondary to nonthrombotic disease treated with en-
dovenous venoplasty and stenting has demonstrated pri-
mary and assisted-primary patency rates of 79% and 100%,
respectively, at 72 months.58,60 Interestingly, patients with
combined obstruction and reflux demonstrated significant
relief in pain and swelling as well as improved quality of life
after undergoing venous stenting, independent of their
untreated deep reflux disease.61 Distinguishing patients
with symptoms secondary to chronic obstruction requires a
high degree of suspicion and a low threshold for further
diagnostic investigations. Identification of such patients,
followed by aggressive endovenous therapy may decrease
the development of late complications associated with CVI.
Evidence. Recognizing chronic obstruction, either
with or without reflux, is necessary to prevent late compli-
cations such as the PTS. This requires a high degree of
suspicion in a symptomatic patient, as pathology is often
undetectable by conventional diagnostic testing. There is
no gold standard when evaluating venous outflow obstruc-
tion. Evidence is lacking for defining the hemodynamic
significance of venous obstruction and its relationship to
anatomic findings, as well as the best way to quantify
obstruction with various imaging or hemodynamic mea-
sures. Anatomically, ascending venography is used to diag-
nose iliofemoral stenosis or occlusion; however, even in
multiple projections, chronic venous webs and partially
recanalized thrombus may not be apparent. Imaging such
as magnetic resonance venography or computed tomogra-
phy can demonstrate extrinsic vein compression, but does
not offer any information on the hemodynamic significance
of such lesions.62,63 Even intravascular ultrasound, which
has been shown to be superior to single plane venography
for morphological diagnosis of iliac venous outflow ob-
struction is not optimal for assessing the hemodynamic
significance of such an obstruction.60 In instances where a
thrombus has been fully lysed, the vein wall remains thick-
ened and may be noncompliant.64 The contribution of a
stiff vein wall to venous pressure is unknown. Furthermore,
the use of a surgical arteriovenous fistula for patients with
chronic obstruction to improve inflow after angioplasty and
stenting is understudied and lacks objective data to guide
its use. Antiplatelet use in venous stenting is variable and
the optimal antithrombotic regimen has yet to be eluci-
dated. Finally, despite academic enthusiasm for a dedicated
JOURNAL OF VASCULAR SURGERY
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Means to achieve goals. Practical measures to achieve
these goals include directed education of primary care
internists to refer these less common patients to specialized
centers after the acute thrombotic episode has been man-
aged. A packet of literature outlining an algorhythm that
defines the indications, evaluation, and therapies will en-
courage increased referral from emergency room and pri-
mary care providers. Lastly, use of noninvasive measures for
the diagnosis of iliofemoral occlusion requires better
standardization.
Recommendations and actions. Measures of success
would be to promote increased use of the American Venous
Forum venous stenting registry (which is ongoing) so that
best practice recommendations can be made, and to devise
a point survey of practice patterns and utilization of Medi-
care procedural use data.
Timeline. The timeline to achieve these landmarks
would be 2 to 5 years.
TOPIC 5
Stratify patients with acute DVT who are at risk for
developing severe PTS
Background. Despite appropriate anticoagulation the-
rapy, between one-third and one-half of all patients with
acute symptomatic DVT will develop PTS, which can be
severe in up to 20% of this population.1,36 Although it is
not possible to foresee the development and course of PTS
in the individual patient, clinical predictors of PTS are
identifiable at the time of acute DVT. Clinical factors at
initial presentation and at 30 days can allow categorization
of patients at risk for severe PTS.44 Proximal DVT involv-
ing the common femoral or iliac veins, elevated body mass
index, previous ipsilateral DVT, and older age are associ-
ated with the development of PTS.1,44 Additionally, in one
study, patients found to have a subtherapeutic international
normalized ratio while on a VKA during the initial first 3
months of anticoagulation have a three-fold risk for devel-
oping PTS.66 Furthermore, patients who demonstrate
symptoms of PTS at 1 month following acute DVT are
predicted to develop severe PTS at 2 years in a dose-
response fashion.44 Interestingly, two hypercoagulable
states, heterozygous FV Leiden and PT 202104, are asso-
ciated with lesser PTS risk.67
Outside of clinical parameters, new data suggest a role
Table III. Risk classification for PTS related to acute DVT
Symptoms Etiology
1  None
2 Mild
3 Moderate
4  Severe
5  Limb-threatening
1  Provoked
2  Unprovokedfor cytokines or adhesion molecules, such as IL-6,ICAM-1, and C-reactive protein, as a surrogate biomarker
for inflammation associated with the transition from acute
DVT to chronic PTS.19,68 Better definition of clinical and
biological parameters that contribute to the formation and
progression of the PTS will improve stratification of DVT
patients who are likely to develop PTS, and thereby guide
management decisions and protocols.
Evidence. The diagnosis of PTS has subjective ele-
ments. Despite the availability of six different classification
scales that have been used to diagnose PTS, there is no
standardized definition of PTS. Only recently has the In-
ternational Society on Thrombosis and Hemostasis put
forth recommendations, suggesting the Villalta PTS scale
be used primarily, complimented by the CEAP classifica-
tion when appropriate.69 No scale currently incorporates
the use of biomarkers in the diagnosis of PTS, mainly
because there is a lack of data on their role in stratifying
PTS.
Although it appears that early PTS symptoms after
DVT correlate with poor long-term outcome, we have yet
to elucidate the underlying pathology of this process. The
mechanism driving the progression of PTS and whether its
course can be halted or even reversed is unknown. Cer-
tainly, the inflammatory response is involved, but its role in
PTS and the relationship between inflammation and ve-
nous reflux and obstruction is unclear. Understanding the
pathology of PTS will need to begin back in the basic
science laboratories before we can progress to clinical
applications.
Means to achieve goals. The measures to be pursued
include development and validation of a DVT clinical score
to predict risk of PTS after DVT, much like the CEAP
score. Secondly, to develop and distribute to practitioners,
particularly primary care and ER physicians, an education
packet-card related to the DVT PTS prediction score.
Recommendations and actions. The DVT PTS risk
prediction score (Table III) could be defined as: S 
symptom severity (1 no overt symptoms, 2mild symp-
toms, 3 moderate symptoms, 4  severe symptoms; 5
limb threatening symptoms); E  provoked versus unpro-
voked; A anatomy; 1) iliofemoral, 2) femoropopliteal, 3)
calf veins; P  pathophysiology: 1) primary; 2) recurrent.
This would best be determined by an expert group consen-
sus panel, as well as follow-up validation studies. An addi-
tional research question to be pursued is a review of the
EAP”
Anat P
1  Calf vein
2  Femoral/Popliteal
3  Iliofemoral
4 Multi-segments  2
1  Primary
2  Recurrent: “Sliterature of PTS with regard to factors that predict ulcer
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with PTS development and severity.
Timeline. The timeline for achieving these goals with
the development and validation of a PTS prediction tool is
approximately 1 to 2 years, and data collection over the
next 5 years.
TOPIC 6
Pharmacological management of PTS
Background. The use of pharmacological agents as
primary or adjuvant therapy in the management of venous
insufficiency and ulceration is limited in the United States.
However, worldwide,“phlebotonic” drugs such as micron-
ized purified flavonoid fraction (MPFF) and horse chestnut
seed extract (HCSE), are commonly used, especially in
warm climate regions where compression therapy is unpop-
ular.57 The active component in HCSE, aescin, is thought
to work via an inhibitory effect on the catalytic breakdown
of capillary wall proteoglycans, as well as by exerting a
positive influence on venous tone and increasing the flow
velocity of venous blood through its anti-inflammatory and
potent vasoconstrictive properties.70 HCSE, the focus of a
Cochrane systematic review, has been shown to improve
signs and symptoms of chronic venous insufficiency com-
pared with placebo.71 One trial suggested that HCSE may
be as efficacious as compression therapy for symptom re-
lief.72 MPFF, like HCSE, has been shown to be effective at
relieving the signs and symptoms of chronic venous insuf-
ficiency in randomized controlled trials.73 In combination
with compression, both MPFF and pentoxifylline have
proven to be effective in ulcer healing compared with
placebo.57 Despite convincing data for the use of pharma-
cological agents in the management of venous disease,
there is currently a lack of legal and standardized practice in
the United States. Randomized trials to evaluate the effi-
cacy and safety of such therapies in an American population
must first be met with a legal acceptance by our governing
bodies.
Evidence. A large body of evidence on the effective-
ness of pharmacologic agents in the management of
chronic venous insufficiency exists amongst the peer-
reviewed literature. Aside from the illegality of such therapies
in the United States, no trial to our knowledge has looked
specifically at the use of these agents in treatment of PTS.
Although the signs and symptoms of primary and second-
ary CVI can be similar, the underlying pathophysiologic
process of PTS is different. The presence of chronic ob-
struction fromDVT seen in PTS differs from reflux second-
ary to valvular incompetence in the absence of obstruction
as seen in CVI. It is unknown if such “phlebotonic” agents
will have the same beneficial effect in PTS as has been
observed in CVI. Furthermore, there is limited evidence on
the use of such pharmacologic agents as a primary thera-
peutic tool (ie, in the absence of compression). We need to
further define the proper indications, ideal dosage, length
of treatment, and safety of these drugs when used in the
long term before we can consider them as standard treat-ment. The data will likely be abstracted first from the
European trial data.
Means to achieve goals. The practical measures to
achieve these objectives would be to formally analyze the
data from the European trials and incorporate the Co-
chrane Database reviews to formulate an information
packet. It is recommended to conduct a study of the
long-term safety and efficacy of HCSE for the treatment
of PTS.
Recommendations and actions. The landmark mea-
sures of success would be the introduction of these medi-
cations into the United States over the next several years,
and to track and determine pentoxifylline (the only avail-
able agent in the United States) use as a surrogate for
dissemination of available evidence at a time point now and
5 to 7 years later.
Timeline. The timeline to achieve these landmarks
would be pentoxifylline utilization at 2 years, and introduc-
tion of new drugs within 5 to 10 years.
CONCLUSION
In summary from Group I, it is clear that one of the
foremost activities is education and dissemination of cur-
rent knowledge regarding PTS prevention and therapy.
This specifically involves evidence based treatment of acute
DVT and preventing DVT recurrence. This must occur at
all levels, including physicians, nurse practitioners, physi-
cian assistants, residents, nurses, etc. Currently, if applied
systematically and consistently, many modalities are already
available to significantly reduce the development of PTS
and thus venous stasis ulcers. Technical advances will allow
early and aggressive thrombus removal, as well as improved
compliance with compression, both of which seem critical
to achieve these goals. Success of these initiatives will also
be highly dependent on industry partnerships that allow the
focused directives we have identified to occur.
Major tools to achieving goals
1. Educational material on preventing DVT and PTS to
primary care providers, ED physicians, and patients;
2. Ramp up thrombolysis/thrombus removal and stent
registries to define who is best served with this therapy;
3. Interface with industry (eg, ECS, pharma, device tech-
nologies) to support specific projects.
PVS6 writing group I members: Frank Vandy, MD,
Anthony Comerota, MD, Susan R. Kahn, MD,MPH, B.K.
Lal, MD, Joanne Lohr, MD, Mark Meissner, MD, Joseph
Caprini, MD, Robert McLafferty, MD, Dean Bender, Gary
Jarvis, Peter Meyer, Diana Wu, Thomas Wakefield, MD.
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